Adicet Bio, Inc. (ACET)
| Market Cap | 242.00M |
| Revenue (ttm) | 9.27M |
| Net Income (ttm) | -55.91M |
| Shares Out | 31.82M |
| EPS (ttm) | -2.70 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 170,597 |
| Open | 7.32 |
| Previous Close | 7.28 |
| Day's Range | 7.25 - 7.89 |
| 52-Week Range | 6.25 - 17.80 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 28.29 (+272.2%) |
| Est. Earnings Date | Nov 4, 2021 |
About ACET
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase 1 clinical study for the treatment of non-Hodgkin's lymphoma. The company a...
Financial Performance
In 2020, Adicet Bio's revenue was $17.90 million, an increase of 1,699.30% compared to the previous year's $995,000. Losses were -$36.68 million, 30.4% more than in 2019.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for Adicet Bio stock is "Strong Buy." The 12-month stock price forecast is 28.29, which is an increase of 272.24% from the latest price.
News
Twist Bioscience Collaborates with Adicet Bio to Accelerate Discovery of Gamma Delta T Cell Cancer Therapeutics
SOUTH SAN FRANCISCO, Calif. & MENLO PARK, Calif. & BOSTON--(BUSINESS WIRE)--Twist Bioscience and Adicet Bio collaboration to accelerate the discovery of gamma delta T cell therapies against five undiscl...
Adicet Bio to Participate in Upcoming Investor Conferences
MENLO PARK, Calif. and BOSTON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer a...
Adicet Bio, Inc. (ACET) Reports Q2 Loss, Tops Revenue Estimates
Adicet Bio, Inc. (ACET) delivered earnings and revenue surprises of 33.33% and 6.96%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Adicet Reports Second Quarter 2021 Financial Results and Provides Business Updates
On track to report top-line interim data from ADI-001 Phase 1 study in Non-Hodgkin's Lymphoma (NHL) by the end of 2021 On track to report top-line interim data from ADI-001 Phase 1 study in Non-Hodgkin'...
Adicet Bio to Participate in Upcoming Investor Conferences
MENLO PARK, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other dis...
Adicet Bio Announces Formation of Scientific Advisory Board
MENLO PARK, Calif and BOSTON, July 15, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and...
Adicet Bio Added to the Russell 2000® Index
MENLO PARK, Calif. and BOSTON, June 28, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer an...
Moving Average Crossover Alert: Adicet Bio (ACET)
Adicet Bio (ACET) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
New Strong Sell Stocks for May 28th
ACET, FURY, KRYS, MRSN, and NBEV have been added to the Zacks Rank #5 (Strong Sell) List on May 28, 2021
Adicet Bio to Participate in Upcoming Investor Conferences
MENLO PARK, Calif., May 18, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other dise...
Adicet Reports First Quarter 2021 Financial Results and Provides Business Updates
MENLO PARK, Calif. and BOSTON, May 17, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies...
Adicet Bio Appoints Dr. Blake Aftab as Vice President of Research
MENLO PARK, Calif. and BOSTON, April 13, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer a...
Adicet Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
MENLO PARK, Calif. and BOSTON, March 11, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer a...
Adicet Bio Announces Initiation of its First-in-Human Phase 1 Trial of ADI-001 for the Treatment of B Cell Non-Hodgki...
MENLO PARK, Calif. and BOSTON, Mass.
Adicet Bio Appoints Dr. Andrew Sinclair to its Board of Directors
MENLO PARK, Calif. and BOSTON, March 04, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer a...
Adicet Bio, Inc. Announces Closing of $152 Million Public Offering and Concurrent Private Placement and Exercise in F...
MENLO PARK, Calif. and BOSTON, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell thera...
Adicet Bio, Inc. Announces Pricing of $135 Million Public Offering of Common Stock and Concurrent Private Placement
MENLO PARK, Calif. and BOSTON, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies fo...
Adicet Bio, Inc. Announces Proposed Public Offering of Common Stock and Concurrent Private Placement
MENLO PARK, Calif. and BOSTON, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies fo...
Adicet: Promising 2021 Therapeutic Initiations, Cash Of $108 Million, And New Management
Adicet Bio is a biotechnology company concentrated on developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet has developed a pre-clinical pipeline of 4 therapeutics cov...
Adicet Bio (ACET) Surges: Stock Moves 5.9% Higher
Adicet Bio (ACET) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Adicet Bio to Participate in Fireside Chat at JMP Securities Hematology Summit
MENLO PARK, Calif., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cance...
Adicet Announces Appointment of Dr. Bastiano Sanna to its Board of Directors
MENLO PARK, Calif. and BOSTON, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapie...
Adicet Reports Third Quarter 2020 Financial Results and Provides Business Update
MENLO PARK, Calif. and BOSTON, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapie...
Adicet Appoints Don Healey, Ph.D., as Chief Technology Officer
MENLO PARK, Calif. and BOSTON, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapie...
Adicet Announces FDA Clearance of IND Application for First-in-Class Allogeneic CAR Gamma-Delta T Cell Therapy
Phase 1 Clinical Study will Evaluate ADI-001 Safety and Efficacy in Patients with B-cell non-Hodgkin's lymphoma Phase 1 Clinical Study will Evaluate ADI-001 Safety and Efficacy in Patients with B-cell n...